|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-1-18
|
|
pubmed:abstractText |
High amounts of intratumoral macrophages have been shown to correlate with poor prognosis in patients with follicular lymphoma (FL) treated with chemotherapy without rituximab. We tried to establish whether intratumoral macrophage count (MC) definitely is able to predict the outcome of FL patients in the rituximab era.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/CD68 antigen, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Teniposide,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BrousseNicoleN,
pubmed-author:CanioniDanielleD,
pubmed-author:FoussardCharlesC,
pubmed-author:KeuppensMarieM,
pubmed-author:LamyThierryT,
pubmed-author:MorchhauserFrankF,
pubmed-author:MounierNicolasN,
pubmed-author:RousseletMarie-ChristineMC,
pubmed-author:SallesGillesG,
pubmed-author:SonetAnneA,
pubmed-author:XerriLucL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
440-6
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18086798-Adult,
pubmed-meshheading:18086798-Aged,
pubmed-meshheading:18086798-Antibodies, Monoclonal,
pubmed-meshheading:18086798-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18086798-Antigens, CD,
pubmed-meshheading:18086798-Antigens, Differentiation, Myelomonocytic,
pubmed-meshheading:18086798-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18086798-Cyclophosphamide,
pubmed-meshheading:18086798-Doxorubicin,
pubmed-meshheading:18086798-Female,
pubmed-meshheading:18086798-Humans,
pubmed-meshheading:18086798-Interferon-alpha,
pubmed-meshheading:18086798-Lymphoma, Follicular,
pubmed-meshheading:18086798-Macrophages,
pubmed-meshheading:18086798-Male,
pubmed-meshheading:18086798-Middle Aged,
pubmed-meshheading:18086798-Prednisone,
pubmed-meshheading:18086798-Prognosis,
pubmed-meshheading:18086798-Prospective Studies,
pubmed-meshheading:18086798-Survival Rate,
pubmed-meshheading:18086798-Teniposide,
pubmed-meshheading:18086798-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
|
|
pubmed:affiliation |
Department of Pathology, Assistance Publique-Hopitaux de Paris, Hôpital Necker-Enfants Malades, Université Paris-Descartes, 149 rue de Sèvres, 75015, Paris, France. danielle.canioni@nck.ap-hop-paris.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
